Patent · US Active

Humanized antibodies against TL1A

US9416185B2 · kind B2 · utility

17Cited by

1References

22Claims

0Family size

Assignee

TEV A Biopharmaceuticals USA, Inc. · US

Inventors

Rodger Smith · Jefferson, US
Palanisamy Kanakaraj · Germantown, US
Viktor Roschke · Rockville, US
Craig Rosen · Laytonsville, US
Bridget A. Cooksey · Rockville, US

Key dates

Filing date	Apr 3, 2014
Grant date	Aug 16, 2016
Priority date	—
Expiry date	Apr 26, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.